WELLESLEY, Mass. — Coley Pharmaceutical Group Inc. said Tuesday its VaxImmune technology is part of a late-stage study launched by GlaxoSmithKline.
Coley granted Glaxo a worldwide licensing contract for use of VaxImmune in vaccines for cancers and certain infectious diseases.
The Glaxo Phase III clinical trial is focusing on its MAGE-A3 product as a lung cancer treatment. The VaxImmune component is aimed at inducing an antibody response to the cancer.
Shares of Coley rose 16 cents to $8.77 in morning trading. Shares of GlaxoSmithKline fell 49 cents to $51.32.
Source : www.chron.com
0 comments:
Post a Comment